The FDA has approved dinutuximab (Unituxin, United Therapeutics), in combination with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), to treat children with high-risk neuroblastoma who are partial responders to previous chemotherapy.
The recommended dose and schedule for dinutuximab is 17.5 mg/m2 per day as a diluted IV infusion over 10 to 20 hours for four consecutive days for up to five cycles. Patients require IV treatment